If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may wonder about the risk of gastroparesis. Recent research has focused on this potential side effect, building on decades of medical knowledge about medication safety. This page reviews current studies and FDA communications to help you understand the evidence.
Building on the need for targeted safety communication, this section examines the clinical evidence linking Ozempic (semaglutide) to gastroparesis. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its prescribing information documents a range of gastrointestinal adverse reactions, which are among the most commonly reported side effects. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, is not explicitly listed as a labeled adverse reaction in the current prescribing information. However, the clinical presentation of gastroparesis—including nausea, vomiting, abdominal pain, and early satiety—overlaps substantially with the gastrointestinal symptoms reported in Ozempic clinical trials. Clinical presentation and diagnosis of gastroparesis typically involve symptoms such as postprandial fullness, nausea, vomiting, bloating, and upper abdominal pain. Diagnosis is confirmed through gastric emptying scintigraphy or other motility studies. The symptoms of gastroparesis can be debilitating and may lead to nutritional deficiencies, weight loss, and reduced quality of life.
Ozempic’s pharmacology involves activation of GLP-1 receptors, which slows gastric emptying as part of its mechanism to reduce postprandial glucose excursions. This pharmacodynamic effect is dose-dependent and can contribute to the gastrointestinal adverse reactions observed in clinical trials. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus include nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms mirror those of gastroparesis, raising mechanistic plausibility that Ozempic-induced delayed gastric emptying could, in susceptible individuals, progress to clinically significant gastroparesis.
Mechanistic pathways linking Ozempic to gastroparesis involve GLP-1 receptor-mediated inhibition of gastric motility. GLP-1 receptors are expressed on vagal afferent neurons and enteric neurons, and their activation reduces antral contractions and pyloric tone, leading to slowed gastric emptying. Chronic exposure to GLP-1 receptor agonists may cause sustained impairment of gastric motility, potentially leading to gastroparesis in patients with underlying risk factors such as diabetic autonomic neuropathy, prior gastrointestinal surgery, or concomitant use of other medications that slow gastric emptying. Risk considerations regarding the adequacy of warnings for Ozempic and gastroparesis are important. The prescribing information lists nausea, vomiting, diarrhea, abdominal pain, and constipation as common adverse reactions, but does not specifically warn about gastroparesis as a distinct adverse event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The serious adverse reactions section includes pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, hypersensitivity, and acute gallbladder disease, but not gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission may leave patients and clinicians unaware of the potential for gastroparesis to develop, particularly in those with persistent or severe gastrointestinal symptoms.
Causation-related considerations for affected patients require careful evaluation. The temporal relationship between Ozempic initiation and onset of gastroparesis symptoms is critical. In clinical trials, gastrointestinal adverse reactions were most common during dose escalation, suggesting an early onset (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, some patients may develop symptoms after prolonged use. The dose-response relationship, with higher rates of gastrointestinal adverse reactions at higher doses (34.0% for 2 mg vs 30.8% for 1 mg), supports a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Exclusion of other causes of gastroparesis, such as diabetes-related autonomic neuropathy, idiopathic gastroparesis, or medication-induced effects from other drugs, is necessary to establish causation. The timeline between exposure and documented harm varies. In clinical trials, gastrointestinal adverse reactions were reported within weeks of initiation, particularly during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). For patients who develop gastroparesis, symptoms may persist or worsen over time, leading to discontinuation of therapy. The prescribing information notes that 3.1% of patients on 0.5 mg and 3.8% on 1 mg discontinued due to gastrointestinal adverse reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This indicates that a subset of patients experiences symptoms severe enough to warrant stopping treatment. In summary, while Ozempic’s prescribing information does not explicitly list gastroparesis as an adverse reaction, the drug’s pharmacological effect on gastric emptying and the high frequency of overlapping gastrointestinal symptoms provide a plausible mechanistic link. The adequacy of current warnings may be insufficient to alert patients and clinicians to the potential for gastroparesis. Affected patients should be evaluated for alternative causes, and a temporal relationship between Ozempic use and symptom onset should be documented. Further research is needed to clarify the incidence and risk factors for Ozempic-associated gastroparesis.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The FDA has not issued a specific warning for gastroparesis with Ozempic, but the prescribing information lists gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain, which overlap with gastroparesis symptoms. The FDA continues to monitor adverse event reports, and patients are advised to report persistent or severe gastrointestinal symptoms to their healthcare provider.
While not explicitly listed as an adverse reaction, Ozempic slows gastric emptying as part of its mechanism, and clinical trials show high rates of gastrointestinal symptoms that mimic gastroparesis. Mechanistic plausibility exists, and patients with risk factors may be more susceptible. Consultation with a healthcare provider is recommended if symptoms develop.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.